Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis

Proft, Fabian; Muche, B.; Spiller, Laura; Rademacher, Judith; Weber, Anne-Katrin; Lüders, S.; Protopopov, Mikhail; Redeker, Imke; Spiller, Inge; Sieper, Joachim; Poddubnyy, Denis

doi:10.1016/j.jbspin.2019.07.007

Cited by 11 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, mean qCRP values were slightly higher than mean routine laboratory CRP values. This is in line with the results for the validation of ASDAS-Q16 17 and SDAI-Q 18. As observed in our other studies in axial patients with SpA16 17 and patients with RA,18 the tendency for slightly higher qCRP values showed almost no influence on the disease activity classification since DAPSA and Q-DAPSA resulted in identical disease activity categories in 98.1%.…”

Section: Discussionsupporting

confidence: 91%

“…This is in line with the results for the validation of ASDAS-Q16 17 and SDAI-Q 18. As observed in our other studies in axial patients with SpA16 17 and patients with RA,18 the tendency for slightly higher qCRP values showed almost no influence on the disease activity classification since DAPSA and Q-DAPSA resulted in identical disease activity categories in 98.1%. Analysing the two patients with discordant disease activity categories of DAPSA and Q-DAPSA, both showed DAPSA and Q-DAPSA values very close to the cutoffs of the respective disease activity categories and only small deviations of routine laboratory CRP and qCRP values (online supplemental table S2).…”

Section: Discussionsupporting

confidence: 91%

“…In other studies, we could already validate a qCRP-based Ankylosing Spondylitis Disease Activity Score (ASDAS-Q) in patients with axial SpA16 17 and a qCRP-based Simplified Disease Activity Index (SDAI-Q) in patients with rheumatoid arthritis (RA) 18. In the current study, we aimed to evaluate a DAPSA using a quick quantitative CRP assay (so called Q-DAPSA).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study

Proft

Schally

Brandt³

et al. 2022

RMD Open

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study aimed to evaluate the Disease Activity index for PSoriatic Arthritis (DAPSA) based on a quick quantitative C reactive protein (qCRP) assay (Q-DAPSA) in a multicentre, prospective, cross-sectional study in patients with psoriatic arthritis (PsA).MethodsThe assessment of prospectively recruited study patients included joint examination and patient reported outcome (PRO) measures (patient global assessment, patient pain assessment). Following, the DAPSA based on a routine laboratory CRP measurement, Q-DAPSA and clinical DAPSA (cDAPSA) were calculated. Cross-tabulations and weighted Cohen’s kappa were performed to analyse the agreement of disease activity categories. Bland-Altman plots and intraclass correlation coefficients were used to determine the agreement of numerical values regarding CRP and qCRP as well as different disease activity scores.ResultsAltogether, 104 patients with PsA could be included in the statistical analysis. With Q-DAPSA, 102 of 104 (98.1%) patients achieved identical disease activity categories in comparison to DAPSA with a weighted Cohen’s kappa of 0.980 (95% CI: 0.952 to 1.000). The agreement between DAPSA and cDAPSA was slightly lower with identical disease activity categories seen in 97 of 104 (93.3%) of patients and with a weighted Cohen’s kappa of 0.932 (95% CI 0.885 to 0.980).ConclusionsThe Q-DAPSA showed an almost perfect agreement with the conventional DAPSA regarding identical disease activity categories. Thus, the Q-DAPSA can be used as a timely available disease activity score in patients with PsA with the additional benefit of CRP involvement. Consequently, the Q-DAPSA could facilitate the implementation of the treat-to-target concept in clinical routine and clinical trials.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study

Proft

Schally

Brandt³

et al. 2022

RMD Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, ASDAS incorporates the perspective of the patient and includes CRP as an objective measure of inflammation while the BASDAI reflects only the patient perspective 35 36. ASDAS has also been validated with a quick-quantitative CRP assay, further improving its feasibility for daily clinical practice 37 38. ASDAS has been shown to be longitudinally associated with syndesmophyte formation 25 27 39.…”

Section: Resultsmentioning

confidence: 99%

“…With over a decade of extensive experience with ASDAS and the accumulated data evidencing its superiority, its choice was imperative 25 35 36 40 90–92. When it is not possible to use the ASDAS, it is better to use the BASDAI than no instrument at all, but we advocate that all efforts are made to implement the ASDAS in daily clinical practice 37 46…”

Section: Discussionmentioning

confidence: 99%

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectivesTo update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA).MethodsFollowing the EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment of axSpA. In a task force meeting, the evidence was presented, discussed, and overarching principles and recommendations were updated, followed by voting.ResultsFive overarching principles and 15 recommendations with a focus on personalised medicine were agreed: eight remained unchanged from the previous recommendations; three with minor edits on nomenclature; two with relevant updates (#9, 12); two newly formulated (#10, 11). The first five recommendations focus on treatment target and monitoring, non-pharmacological management and non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice pharmacological treatment. Recommendations 6–8 deal with analgesics and discourage long-term glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for pure axial involvement. Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i)) and targeted synthetic DMARDs (tsDMARDs, ie, Janus kinase inhibitors) for patients who have Ankylosing Spondylitis Disease Activity Score ≥2.1 and failed ≥2 NSAIDs and also have either elevated C reactive protein, MRI inflammation of sacroiliac joints or radiographic sacroiliitis. Current practice is to start a TNFi or IL-17i. Recommendation 10 addresses extramusculoskeletal manifestations with TNF monoclonal antibodies preferred for recurrent uveitis or inflammatory bowel disease, and IL-17i for significant psoriasis. Treatment failure should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities (#11). If active axSpA is confirmed, switching to another b/tsDMARD is recommended (#12). Tapering, rather than immediate discontinuation of a bDMARD, can be considered in patients in sustained remission (#13). The last recommendations (#14, 15) deal with surgery and spinal fractures.ConclusionsThe 2022 ASAS-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

show abstract

Vitamin D status in ankylosing spondylitis patients: Relation to bone health, disease activity, functional status, spine mobility and enthesitis

El-Mansoury

El-Karim

et al. 2020

The Egyptian Rheumatologist

View full text Add to dashboard Cite

Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis

Cited by 11 publications

References 14 publications

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Vitamin D status in ankylosing spondylitis patients: Relation to bone health, disease activity, functional status, spine mobility and enthesitis

Contact Info

Product

Resources

About